Dec 13 2024 32 mins 31
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms.
In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma.
To learn more about the topics in this episode:
- Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
- Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
- Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect
- Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy
See omnystudio.com/listener for privacy information.
